Invitation to conference call for updated results from the LYMRIT 37-01 Phase 1/2 trial, to be presented at ASH
Oslo, Norway, 8 December 2017
Nordic Nanovector ASA (OSE: NANO) will host a conference call and audio cast on Monday 11 December at 08:00 CET to present the updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® in patients with relapsed/refractory (R/R) indolent non-Hodgkin’s lymphoma (iNHL).
These results will be presented at the 59th Annual American Society of Hematology (ASH) meeting on 9-12 December 2017 in Atlanta, GA, USA.
The poster will be published on Nordic Nanovector’s website (www.nordicnanovector.com) in the section: /what-we-do/scientific-background/scientific-posters on Sunday 10 December 2017 at 15:00 CET.
Conference call and audio cast details:
Please join the conference 5-10 minutes prior to the start time. You will be asked to provide the confirmation code or the title of the conference.
Event Conference Title: Nordic Nanovector – ASH update
Date and time: Monday 11 December 2017 at 08:00 CET
Confirmation Code: 2436440
|Norway||+47 2350 0296|
|Switzerland||+41 44 580 1022|
|Sweden||+46 8 5065 3942|
|United Kingdom and International||+44 330 336 9411|
|United States||+1 720-452-9217|
If you want to follow the presentation via audio cast with sound and slides, please use the following link: http://webtv.hegnar.no/presentation.php?webcastId=75022840
The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Presentation/2017 from 08:00 CET on 11 December 2017.
For further information, please contact:
IR enquiries: Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Media enquiries: Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.
The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com